Advancing SCLC Care: Tarlatamab as a Promising First-Line Option
Ariel Lopez-Chavez, MD, discusses the potential of tarlatamab and its use in the frontline setting for the treatment of patients with small cell lung cancer.
Evaluating PD-L1 Therapy in SCLC
Ariel Lopez-Chavez, MD, discusses some of the research on evaluating PD-L1 therapy for patients with small cell lung cancer.
First- and Second-Line Treatments in SCLC
Ariel Lopez-Chavez, MD, discusses available frontline options for patients with small cell lung cancer, then moves into second-line treatments.